GlaxoSmithKline (GSK -0.1%) has agreed to support the production of the COVID-19 vaccine candidate developed by Novavax (NVAX -7.1%).
In an agreement reached with the U.S.-based vaccine developer and the UK Government Vaccines Taskforce, GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England for up to 60M vaccine doses for use in the U.K.
The transfer of technology is expected to begin immediately leading to production to start as early as May, GSK said in a statement.
Under an advance purchase agreement with Novavax, the U.K. government has secured 60M doses of the COVID-19 candidate which met its primary endpoint with an efficacy of 89.3% in a late-stage trial conducted in the country.
